Summit Therapeutics plc (SMMT): Price and Financial Metrics
GET POWR RATINGS... FREE!
SMMT POWR Grades
- SMMT scores best on the Growth dimension, with a Growth rank ahead of 87.04% of US stocks.
- The strongest trend for SMMT is in Stability, which has been heading down over the past 177 days.
- SMMT's current lowest rank is in the Momentum metric (where it is better than 4.75% of US stocks).
SMMT Stock Summary
- With a price/sales ratio of 1,741.74, SUMMIT THERAPEUTICS INC has a higher such ratio than 99.67% of stocks in our set.
- With a year-over-year growth in debt of 18,547.12%, SUMMIT THERAPEUTICS INC's debt growth rate surpasses 99.78% of about US stocks.
- Revenue growth over the past 12 months for SUMMIT THERAPEUTICS INC comes in at -61.03%, a number that bests merely 3.35% of the US stocks we're tracking.
- Stocks that are quantitatively similar to SMMT, based on their financial statements, market capitalization, and price volatility, are JANX, AKTS, SLDP, VERV, and BTAI.
- Visit SMMT's SEC page to see the company's official filings. To visit the company's web site, go to www.summitplc.com.
SMMT Valuation Summary
- SMMT's price/earnings ratio is -15.6; this is 167.24% lower than that of the median Healthcare stock.
- SMMT's EV/EBIT ratio has moved down 7.3 over the prior 98 months.
Below are key valuation metrics over time for SMMT.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| SMMT | 2023-03-24 | 1741.7 | 9.7 | -15.6 | -13.9 |
| SMMT | 2023-03-23 | 1682.4 | 9.4 | -15.1 | -13.4 |
| SMMT | 2023-03-22 | 1652.6 | 9.2 | -14.8 | -13.1 |
| SMMT | 2023-03-21 | 1632.9 | 9.1 | -14.6 | -13.0 |
| SMMT | 2023-03-20 | 1613.0 | 9.0 | -14.4 | -12.8 |
| SMMT | 2023-03-17 | 1652.6 | 9.2 | -14.8 | -13.1 |
SMMT's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- SMMT has a Quality Grade of D, ranking ahead of 7.27% of graded US stocks.
- SMMT's asset turnover comes in at 0.006 -- ranking 406th of 682 Pharmaceutical Products stocks.
- EDIT, SAGE, and SVRA are the stocks whose asset turnover ratios are most correlated with SMMT.
The table below shows SMMT's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.006 | 1 | -10.188 |
| 2020-12-31 | 0.009 | 1 | -12.994 |
| 2019-10-31 | -0.197 | 1 | -4.153 |
| 2019-07-31 | -0.198 | 1 | -4.482 |
| 2019-04-30 | 0.605 | 1 | 1.189 |
| 2019-01-31 | 0.604 | 1 | 0.877 |
SMMT Price Target
For more insight on analysts targets of SMMT, see our SMMT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $4.50 | Average Broker Recommendation | 1.5 (Moderate Buy) |
SMMT Stock Price Chart Interactive Chart >
SMMT Price/Volume Stats
| Current price | $1.77 | 52-week high | $5.78 |
| Prev. close | $1.75 | 52-week low | $0.66 |
| Day low | $1.75 | Volume | 1,001,200 |
| Day high | $1.87 | Avg. volume | 2,950,600 |
| 50-day MA | $2.42 | Dividend yield | N/A |
| 200-day MA | $1.83 | Market Cap | 1.23B |
Summit Therapeutics plc (SMMT) Company Bio
Summit Therapeutics plc operates as a biopharmaceutical company primarily in the United Kingdom and the Unites States. It focuses on the discovery, development, and commercialization of novel medicines to treat the Duchenne Muscular Dystrophy (DMD), a fatal muscle wasting disease; and infections caused by Clostridium difficile bacteria (CDI). The company was founded in 2003 and is based in Abingdon, England.
Latest SMMT News From Around the Web
Below are the latest news stories about SUMMIT THERAPEUTICS INC that investors may wish to consider to help them evaluate SMMT as an investment opportunity.
10 Penny Stocks with Insider BuyingIn this piece, we will take a look at ten penny stocks with insider buying. For more penny stocks, head on over to 5 Penny Stocks with Insider Buying. With the first quarter of 2023 coming to an end, the stock market continues to be in a topsy-turvy environment. 2023 was off to a strong […] |
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022MENLO PARK, Calif., March 09, 2023--Summit Therapeutics announces its Q4 and year-ended 2022 earnings and will host a conference call at 9am EST today (March 9, 2023). |
Summit Therapeutics Closes Fully-Subscribed $500 Million Rights OfferingMENLO PARK, Calif., March 03, 2023--Summit Therapeutics announces the closing of its fully-subscribed, $500 million rights offering. Summit will also host an earnings call on March 9. |
Summit Therapeutics’ Rights Offering Nearing Expiration DateMENLO PARK, Calif., February 23, 2023--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Time on March 1, 2023 (the "Expiration Date"). As a reminder, the subscription price per share shall be equal to the lesser of (i) $1.05 per share or (ii) the volume weighted-average price of the Company’s common stock for the five consecutive trading days through an |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayGood morning! |
SMMT Price Returns
| 1-mo | -1.67% |
| 3-mo | -58.35% |
| 6-mo | 48.74% |
| 1-year | -31.40% |
| 3-year | -25.32% |
| 5-year | -86.28% |
| YTD | -58.35% |
| 2022 | 57.99% |
| 2021 | -42.77% |
| 2020 | 193.75% |
| 2019 | 39.13% |
| 2018 | -89.62% |
Continue Researching SMMT
Here are a few links from around the web to help you further your research on Summit Therapeutics plc's stock as an investment opportunity:Summit Therapeutics plc (SMMT) Stock Price | Nasdaq
Summit Therapeutics plc (SMMT) Stock Quote, History and News - Yahoo Finance
Summit Therapeutics plc (SMMT) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...